NCT06264635

Evaluating the Efficacy of Platelet-Rich-Plasma (PRP) for Erectile Dysfunction

Pilot Randomized Controlled Trial Evaluating the Efficacy of Platelet-Rich-Plasma (PRP) for Erectile Dysfunction
University of Manitoba·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Erectile Dysfunction
Drug/Device/Intervention
Platelet-Rich-Plasma
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
University of Manitoba
Location
Winnipeg, Canada
Timeline & enrollment
Phase
Phase 1
Start date
Mar 01, 2024
End date
Mar 01, 2025
Enrollment
60 participants
Primary outcome

International Index of Erectile Function (IIEF)

Summary

There is great interest in restorative therapies (platelet-rich plasma (PRP) injections,
 shockwave therapy and stem cell therapy) for ED given their non-invasive nature. However,
 data is still limited and requires further research prior to widespread adoption.
 Unfortunately, therapies such as PRP injections are being widely used without clinical
 evidence demonstrating its safety or effectiveness for the treatment of erectile dysfunction.
 2-7 To date, there are no treatments that address the underlying cause of endothelial
 dysfunction, although low-intensity shockwave therapy for ED has shown promising results.
 Platelet-derived therapies targeting inflammation and promoting tissue/nerve regeneration and
 may represent a potential treatment option towards this direction. The investigators propose
 to perform Canada's first pilot RCT to evaluate and safety and efficacy of PRP for the
 treatment of ED.

ICD-10 classifications
Orgasmic dysfunctionOther disorders of penisOther specified disorders of penisSexual dysfunction, not caused by organic disorder or diseaseTesticular dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06264635
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06264635 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Manitoba and is currently Not yet recruiting. The study focuses on Erectile Dysfunction. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.